Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.
Baljevic M, et al. Among authors: stellrecht cm.
Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.
Ann Hematol. 2017.
PMID: 28337527
Free PMC article.
Clinical Trial.